23andMe SPAC Presentation Deck slide image

23andMe SPAC Presentation Deck

Pharmaceutical Industry 7 years average time-to-IND¹ ~90% failure rate² >> 23andMe ~4 years for our CD96 drug 2X increase in probability of success³ NATURE PUBLICATION The support of human genetic evidence for approved drug indications Nelson et. al 2015 IND = Investigational New Drug Application. fdareview.org, "The Drug Development and Approval Process" (2020). 2 Probability of success for a drug to be approved is estimated to be <12%. PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). 3 Nature Publication, "The support of human genetic evidence for approved drug indications" (2015). 23andMe Can Efficiently Develop Novel Therapeutics by Power, Need and Speed 23andMe Confidential and Proprietary Information 22
View entire presentation